Current and upcoming therapies to modulate skin scarring and fibrosis
Skin is the largest organ of the human body. Being the interface between the body and the
outer environment, makes it susceptible to physical injury. To maintain life, nature has …
outer environment, makes it susceptible to physical injury. To maintain life, nature has …
Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - Taylor & Francis
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions
PP Sfikakis - TNF pathophysiology, 2010 - karger.com
Results from clinical trials of biologic anti-TNF drugs performed in the late 1990s confirmed
the biological relevance of TNF function in the pathogenesis of chronic noninfectious …
the biological relevance of TNF function in the pathogenesis of chronic noninfectious …
Overlap connective tissue disease syndromes
L Iaccarino, M Gatto, S Bettio, F Caso… - Autoimmunity …, 2013 - Elsevier
Overlap Syndromes (OSs) have been defined as entities satisfying classification criteria of at
least two connective tissue diseases (CTDs) occurring at the same or at different times in the …
least two connective tissue diseases (CTDs) occurring at the same or at different times in the …
Immunogenicity of anti-TNF-α agents in autoimmune diseases
N Emi Aikawa, JF de Carvalho… - Clinical reviews in …, 2010 - Springer
Prognosis of several autoimmune diseases, especially rheumatoid arthritis (RA), ankylosing
spondylitis, Crohn's disease (CD), and psoriasis, usually refractory to conventional treatment …
spondylitis, Crohn's disease (CD), and psoriasis, usually refractory to conventional treatment …
Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury
SA Pendergrass, E Hayes, G Farina, R Lemaire… - PloS one, 2010 - journals.plos.org
Background Pulmonary arterial hypertension (PAH) is a common complication for
individuals with limited systemic sclerosis (lSSc). The identification and characterization of …
individuals with limited systemic sclerosis (lSSc). The identification and characterization of …
Articular involvement in systemic sclerosis
Articular involvement is frequent in SSc. It contributes to disability and compromises patients'
quality of life. Different aspects of articular involvement have been described, ranging from …
quality of life. Different aspects of articular involvement have been described, ranging from …
Systemic sclerosis: Current concepts of skin and systemic manifestations
DR Pearson, VP Werth, L Pappas-Taffer - Clinics in Dermatology, 2018 - Elsevier
Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan
system involvement and significant associated morbidity and mortality. Cutaneous signs and …
system involvement and significant associated morbidity and mortality. Cutaneous signs and …
Assessment of skin involvement in systemic sclerosis
Skin involvement in SSc is an important marker of disease activity, severity and prognosis,
making the assessment of skin a key issue in SSc clinical research. We reviewed the …
making the assessment of skin a key issue in SSc clinical research. We reviewed the …
[PDF][PDF] Scleroderma overlap syndrome
A Balbir-Gurman, Y Braun-Moscovici - IMAJ-Israel Medical Association …, 2011 - ima.org.il
Background: Overlap syndrome is an entity that satisfies the criteria of at least two
connective tissue diseases (CTD). These conditions include systemic sclerosis (SSc) …
connective tissue diseases (CTD). These conditions include systemic sclerosis (SSc) …